Turning powerful new Complement System insights into innovative treatments

Developing the next generation of complement medicines

Turning powerful new Complement System insights into innovative treatments

Developing the next generation of complement medicines

Geographic atrophy (dry age-related macular degeneration) is a chronic eye condition that affects millions – and for which there is currently no available treatment. The disease is related to Complement System disorders.

Through an extensive programme of translational research we have gained powerful new insights into the ways the Complement System works and how it is dysregulated in age-related macular degeneration.

We are now using these insights to develop a portfolio of treatments for Complement-related diseases including age-related macular degeneration, each with a high unmet clinical need.

About Complement Therapeutics (CTx)

World-leading Complement System expertise 

Complement Therapeutics is a spin-out from The University of Manchester. Its founders have international reputations and world-leading Complement System expertise. 

In particular, the ground breaking research conducted by the founders has led to valuable new insights regarding the role of complement in both ocular and systemic diseases. Of particular note is the research conducted into the role of FHR proteins in age-related macular degeneration (Cipriani and Clark et al., Nat. Comm., 2020, Cipriani and Unwin et al., Am J Hum Genet, 2021).

Based on such insights, the company is focused on the research and development of novel therapeutic approaches to address unmet needs in diseases related to complement dysregulation. 

In developing such therapies, multiple platforms are being pursued including AAV gene therapies as well as protein-based approaches, building on our original patented research and each with the potential to transform lives. 

Alongside our therapeutic strategy, the Company has developed a highly novel mass spectrometry platform (the Complement Precision Medicine platform) enabling the simultaneous measurement of >30 complement proteins from a systemic blood sample.

Our platforms


Our immediate focus with our lead asset CTx001 is the treatment of Geographic Atrophy (late dry age-related macular degeneration), where no licensed treatment is currently available.  CTx001 is in pre-clinical development as an AAV based gene therapy for the targeted treatment of Geographic Atrophy. Harnessing the benefits of gene therapy and our unique mechanism of action, CTx001 has the potential to transform the lives of people living with GA.

In addition, we are developing therapeutics that are aimed at systemic modulation of the complement system. We anticipate that these assets will meet the needs of a wide range of patients with complement-mediated disease. 

Gene therapies

Protein therapies

Multiple platforms

Office 20, 4th Floor
Central Working White City
Translation and Innovation Hub
84 Wood Lane
London, W12 0BZ
United Kingdom


Created by HTP Digital